Cornerstone BioPharma, Inc. and Athlon Pharmaceuticals Sign Co-Promotion Agreement
Cary, NC, June 06, 2006 --(PR.com)-- Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has signed a co-promotion agreement with Athlon Pharmaceuticals (Athlon). This agreement names Athlon as a partner in the promotion of Balacet 325™, a mild-to-moderate pain medication.
Balacet 325 was approved by the Food and Drug Administration in May 2005 and has since been promoted to pain specialists and primary care providers by Cornerstone BioPharma’s sales force. Commencing immediately, the Athlon sales force will co-promote Balacet 325, significantly increasing awareness, promotional efforts and reach of the medication. This partnership represents a significant expansion into the $14 billion U.S. pain market and will serve to increase the recognition of Balacet 325 among healthcare providers.
Commenting on the agreement, Athlon President Jeff Mason said, “We are very excited to be partnering with Cornerstone. The market demand for pain medications with lower levels of acetaminophen such as Balacet 325 is growing and will only continue to do so. Including Balacet 325 in our pain line will further strengthen Athlon's position in the specialty area of pain management."
“The strategic value of this partnership for Balacet 325 quickly became clear during our discussions with Athlon,” said Craig Collard, CEO of Cornerstone BioPharma. "Athlon’s experienced pain sales force is deeply entrenched in the market and will allow us to reach new marketplaces and increase our overall market share."
In March 2006 Cornerstone BioPharma announced a co-promotion agreement with ASCEND Therapeutics naming the company a partner in the promotion of Balacet 325. Since that announcement, the ASCEND sales force has co-promoted Balacet 325 with a focus on obstetrics and gynecology healthcare providers.
###
About Cornerstone
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.
About Athlon Pharmaceuticals
Athlon Pharmaceuticals, Inc. (www.athlonpharm.com), with offices in Birmingham, AL and Jackson, MS, is a branded specialty pharmaceutical company focusing on the development and marketing of prescription products in the areas of pain, respiratory and allergy. Athlon is strategically pursuing product acquisitions, partnerships and product development to enhance its strength, reach and position in the specialty pharmaceuticals arena.
CONTACT: Jonathan Jordan
919 Marketing/919.557.7890
jjordan@919marketing.com
Balacet 325 was approved by the Food and Drug Administration in May 2005 and has since been promoted to pain specialists and primary care providers by Cornerstone BioPharma’s sales force. Commencing immediately, the Athlon sales force will co-promote Balacet 325, significantly increasing awareness, promotional efforts and reach of the medication. This partnership represents a significant expansion into the $14 billion U.S. pain market and will serve to increase the recognition of Balacet 325 among healthcare providers.
Commenting on the agreement, Athlon President Jeff Mason said, “We are very excited to be partnering with Cornerstone. The market demand for pain medications with lower levels of acetaminophen such as Balacet 325 is growing and will only continue to do so. Including Balacet 325 in our pain line will further strengthen Athlon's position in the specialty area of pain management."
“The strategic value of this partnership for Balacet 325 quickly became clear during our discussions with Athlon,” said Craig Collard, CEO of Cornerstone BioPharma. "Athlon’s experienced pain sales force is deeply entrenched in the market and will allow us to reach new marketplaces and increase our overall market share."
In March 2006 Cornerstone BioPharma announced a co-promotion agreement with ASCEND Therapeutics naming the company a partner in the promotion of Balacet 325. Since that announcement, the ASCEND sales force has co-promoted Balacet 325 with a focus on obstetrics and gynecology healthcare providers.
###
About Cornerstone
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.
About Athlon Pharmaceuticals
Athlon Pharmaceuticals, Inc. (www.athlonpharm.com), with offices in Birmingham, AL and Jackson, MS, is a branded specialty pharmaceutical company focusing on the development and marketing of prescription products in the areas of pain, respiratory and allergy. Athlon is strategically pursuing product acquisitions, partnerships and product development to enhance its strength, reach and position in the specialty pharmaceuticals arena.
CONTACT: Jonathan Jordan
919 Marketing/919.557.7890
jjordan@919marketing.com
Contact
Cornerstone BioPharma
Jonathan Jordan
919-577-7890
www.cornerstonebiopharma.com
Jonathan Jordan
919-577-7890
www.cornerstonebiopharma.com
Contact
Categories